# A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

> **NCT05800366** · PHASE2 · RECRUITING · sponsor: **Jennifer Crombie, MD** · enrollment: 41 (estimated)

## Conditions studied

- Lymphoma
- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Polatuzumab
- **DRUG:** Rituximab
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT05800366
- **Lead sponsor:** Jennifer Crombie, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-06
- **Primary completion:** 2026-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05800366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05800366, "A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05800366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*